Late-acquired ISA was observed in 5.1% of patients after DES implantation and is related to regional vessel positive remodelling. The relationship between late-acquired ISA and long-term adverse outcomes (e.g. stent thrombosis) requires further analysis.
The novel VESTAsync-eluting stent was effective in reducing LL and neointimal hyperplasia at 4 and 9 months, with no evidence of late catch-up by quantitative coronary angiography or intravascular ultrasound.
This first-in-human experience with a novel self-expanding heart valve showed low rates of procedural mortality, major stroke and pacemaker implantation, and good performance outcomes.
BackgroundTranscatheter aortic valve implantation (TAVI) is a well-established
procedure; however, atrioventricular block requiring permanent pacemaker
implantation (PPI) is a common complication.ObjectivesTo determine the incidence, predictors and clinical outcomes of PPI after
TAVI, focusing on how PPI affects left ventricular ejection fraction (LVEF)
after TAVI.MethodsThe Brazilian Multicenter TAVI Registry included 819 patients submitted to
TAVI due to severe aortic stenosis from 22 centers from January/2008 to
January/2015. After exclusions, the predictors of PPI were assessed in 670
patients by use of multivariate regression. Analysis of the ROC curve was
used to measure the ability of the predictors; p < 0.05 was the
significance level adopted.ResultsWithin 30 days from TAVI, 135 patients (20.1%) required PPI. Those patients
were older (82.5 vs. 81.1 years; p = 0.047) and mainly of the male sex
(59.3% vs 45%; p = 0.003). Hospital length of stay was longer in patients
submitted to PPI (mean = 15.7 ± 25.7 vs. 11.8 ± 22.9 days; p
< 0.001), but PPI affected neither all-cause death (26.7% vs. 25.6%; p =
0.80) nor cardiovascular death (14.1% vs. 14.8%; p = 0.84). By use of
multivariate analysis, the previous presence of right bundle-branch block
(RBBB) (OR, 6.19; 3.56-10.75; p ≤ 0.001), the use of
CoreValve® prosthesis (OR, 3.16; 1.74-5.72; p ≤
0.001) and baseline transaortic gradient > 50 mm Hg (OR, 1.86; 1.08-3.2;
p = 0.025) were predictors of PPI. The estimated risk of PPI ranged from 4%,
when none of those predictors was present, to 63%, in the presence of all of
them. The model showed good ability to predict the need for PPI: 0.69
(95%CI: 0.64 - 0.74) in the ROC curve. The substudy of 287 echocardiograms
during the 1-year follow-up showed worse LVEF course in patients submitted
to PPI (p = 0.01).ConclusionBRD prévio, gradiente aórtico médio > 50 mmHg e
CoreValve® são preditores independentes de implante de MPD
pós-TAVI. Ocorreu implante de MPD em aproximadamente 20% dos casos de
TAVI, o que prolongou a internação hospitalar, mas não
afetou a mortalidade. O implante de MPD afetou negativamente a FEVE
pós-TAVI.
Some degree of myocardial injury was detected in two-thirds of patients post TAVR, especially in those undergoing TA-TAVR or presenting with major procedural complications. A greater rise in CK-MB levels associated with greater acute and late mortality, imparting a negative impact on left ventricular function.
The aim of this study was to compare transcatheter aortic valve replacement (TAVR) with the Acurate neo (NEO) and Evolut PRO (PRO) devices. BACKGROUND The NEO and PRO bioprostheses are 2 next-generation self-expanding devices developed for TAVR. METHODS The NEOPRO (A Multicenter Comparison of Acurate NEO Versus Evolut PRO Transcatheter Heart Valves) registry retrospectively included patients who underwent transfemoral TAVR with either NEO or PRO valves at 24 centers between January 2012 and March 2018. One-to-one propensity score matching resulted in 251 pairs. Pre-discharge and 30-day Valve Academic Research Consortium (VARC)-2 defined outcomes were evaluated. Binary logistic regression was performed to adjust the treatment effect for propensity score quintiles. RESULTS A total of 1,551 patients (n = 1,263 NEO; n = 288 PRO) were included. The mean age was 82 years, and the mean Society of Thoracic Surgeons score was 5.1%. After propensity score matching (n = 502), VARC-2 device success (90.6% vs. 91.6%; p = 0.751) and predischarge moderate to severe (II+) paravalvular aortic regurgitation (7.3% vs. 5.7%; p = 0.584) were comparable between the NEO and PRO groups. Furthermore, there were no significant differences in any 30-day clinical outcome between matched NEO and PRO pairs, including all-cause mortality (3.2% vs. 1.2%; p = 0.221), stroke (2.4% vs. 2.8%; p = 1.000), new permanent pacemaker implantation (11.0% vs. 12.8%; p = 0.565), and VARC-2 early safety endpoint (10.6% vs. 10.4%; p = 1.000). Logistic regression on the unmatched cohort confirmed a similar risk of VARC-2 device success, paravalvular aortic regurgitation II+, and 30-day clinical outcomes after NEO and PRO implantation. CONCLUSIONS In this multicenter registry, transfemoral TAVR with the NEO and PRO bioprostheses was associated with high device success, acceptable rates of paravalvular aortic regurgitation II+, and good 30-day clinical outcomes. After adjusting for potential confounders, short-term outcomes were similar between the devices.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.